Short Article
Gorka Orive
Abstract
Current therapeutic strategies in Alzheimer’s disease (AD) are focus on the elimination of Aβ plaques. However, clinical benefits are poor as they are applied when the disease is already advanced. To succeed, all these approaches and future emerging therapies should be applied at a very early stage of the disease (before clinical symptoms appear). We have discovered and preliminary tested in a significant number of patients an accurate and non-invasive tool to identify candidates that suffer from mild cognitive impairment (MCI) and AD. This finding may revolutionize the fields of diagnostics, pharmaceutical development and decision making for patient care. We were able to detect a specific molecule (biomarker) in saliva that may help to identify those patients with MCI and/or AD from healthy status.